For hyperuricemic patients with or without gout, 200 mg topiroxostat was the most effective therapeutic option, However, it was associated with a raised risk of adverse events.

A Bayesian network meta-analysis sought to investigate the relative safety and effectiveness of topiroxostat at different doses for the management of hyperuricemic people with or without gout.

In this study, indirect and direct evidences from various randomized controlled trials (RCTs) were collected to compare placebo, topiroxostat at different doses, and 200 mg allopurinol to treat hyperuricemic people without or with gout.

Overall, 5 RCTs, incorporating 733 participants fulfilled the inclusion criteria of the study. The number of people who had attained a target serum uric acid level was considerably greater in the 200 mg topiroxostat group when compared to the placebo group (odds ratio: 1,023). Furthermore, the number of people who had attained the target serum uric acid level was remarkably greater with topiroxostat at other dosages and allopurinol when compared to placebo.

The ranking probability on the basis of surface under the cumulative ranking (SUCRA) curve revealed that 200 mg topiroxostat was more likely to attain the best target serum uric acid level. This was subsequently followed by 80 mg topiroxostat, 200 mg allopurinol, 120 mg topiroxostat, 160 mg topiroxostat, 60 mg topiroxostat, 40 mg topiroxostat, and placebo. Compared to 40 mg topiroxostat, 60 mg topiroxostat, and 200 mg topiroxostat groups, the placebo group exhibited a reduced frequency of adverse events.

In hyperuricemic people with or without gout, 200 mg topiroxostat was more likely to attain the best target serum uric acid level, with an increased risk of adverse events.